BAC and LFB Biotechnologies to Develop Custom Ligand for Purifying Recombinant Factor VIIa
BAC BV, the Bio Affinity Company, announced that it has entered into a collaboration with LFB Biotechnologies, a wholly owned subsidiary of LFB S.A., a biopharmaceutical company working in the highly specialized field of plasma-derived medicinal and biotech products. Working with LFB, BAC will discover and develop a custom CaptureSelect ligand for the purification of a recombinant Factor VIIa product - an essential protein for certain blood coagulation disorders - developed by LFB with GTC Biotherapeutics. The CaptureSelect ligand has the potential to obtain high purity in downstream processing while enhancing the cost reduction benefits of the transgenic Expression system developed by LFB and GTC. LFB and GTC are producing Factor VIIa in the milk of animals that express this recombinant protein during lactation.
BAC has a proven reputation for the rapid discovery and development of customized ligands for a wide range of affinity applications from the purification of monoclonal antibodies and viruses, to plasma proteins. The CaptureSelect ligands are suitable and available for use at commercial biomanufacturing scale and for bench research.
"Our expertise in the custom design of affinity ligands makes BAC a great match for LFB in this project," commented Laurens Sierkstra, CEO of BAC. "Our technology platform enables us to produce ligands that are not only highly specific for the target protein, but will generate a very pure product in a single purification step. We are very much looking forward to working with LFB to develop a ligand for their recombinant Factor VIIa protein that will help to simplify and streamline the purification process."
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Solanum_wallacei
Oak_wilt
Urinary_tract_infection
Colletotrichum_pisi
